

3 September 2008

Results of first patient treated with VitroGro®

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** today announced the results of the first patient treated with VitroGro®. These results are summarised in the attached update.

Mrs Dot Harrison, a 70-year-old grandmother suffered from a venous ulcer on her right ankle which had not healed with conventional dressings. Following treatment with VitroGro® her venous ulcer reduced in area by more than 60 per cent in only 21 days, there was a marked improvement in the health of the tissue at the edge of the wound, and full healing is expected. There were no adverse reactions.

The CEO of Tissue Therapies, Dr Steven Mercer, said while the clinical progress of one patient is not conclusive, they are very excited by these results because this is how they expected VitroGro® to perform clinically.

“There is no doubt that the rapid reduction in ulcer size and improvement in health of the skin in the wound area are highly unusual for a chronic venous ulcer,” said Dr Mercer.

“With the use of VitroGro®, it appears that Mrs Harrison’s ulcer is healing in a way that is exceptional.

“We are delighted for her and look forward to receiving the rest of the clinical results.”

Further information: Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: 07 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com

